Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

abstract：OBJECTIVE:To assess the differences between patients with hepatic insufficiency and healthy subjects with regard to the pharmacokinetics, cardiac safety and overall safety of ebastine and its active metabolite carebastine. DESIGN:Open-label parallel-group study. PARTICIPANTS:24 patients with varying degrees of hepati...

journal_title：Clinical pharmacokinetics

authors： Lasseter KC,Dilzer SC,Vargas R,Waldman S,Noveck RJ

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase currently being developed for the management of hyperuricemia in patients with gout. OBJECTIVE:To investigate the pharmacokinetics, pharmacodynamics and safety of febuxostat over a range of oral doses in healthy subjects. METHODS:In a...

journal_title：Clinical pharmacokinetics

authors： Khosravan R,Grabowski BA,Wu JT,Joseph-Ridge N,Vernillet L

更新日期：2006-01-01 00:00:00

abstract：:Despite progress in the treatment of metastatic colorectal cancer (mCRC) in the last 15 years, it is still a condition with a relatively low 5-year survival rate. Panitumumab, a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR), is able to prolong survival in patients with mC...

journal_title：Clinical pharmacokinetics

authors： Ketzer S,Schimmel K,Koopman M,Guchelaar HJ

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without liver function impairment. METHODS:Cross-sectional, comparative study enrolling HIV-infected adults receiving lopinavir/rito...

journal_title：Clinical pharmacokinetics

authors： Moltó J,Valle M,Blanco A,Negredo E,DelaVarga M,Miranda C,Miranda J,Domingo P,Vilaró J,Tural C,Costa J,Barbanoj MJ,Clotet B

更新日期：2007-01-01 00:00:00

abstract：OBJECTIVE:To study the pharmacokinetics of micafungin in intensive care patients and assess pharmacokinetic (PK) target attainment for various dosing strategies. METHODS:Micafungin PK data from 20 intensive care unit patients were available. A population-PK model was developed. Various dosing regimens were simulated: ...

journal_title：Clinical pharmacokinetics

authors： Martial LC,Ter Heine R,Schouten JA,Hunfeld NG,van Leeuwen HJ,Verweij PE,de Lange DW,Pickkers P,Brüggemann RJ

更新日期：2017-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Vicriviroc is a small-molecule CCR5 antagonist currently in development for the treatment of HIV in patients on a regimen containing a ritonavir-boosted protease inhibitor. As renal disease and renal dysfunction are prevalent in the HIV-infected population, patients with varying degrees of rena...

journal_title：Clinical pharmacokinetics

authors： Kasserra C,Sansone-Parsons A,Keung A,Tetteh E,Assaf M,O'Mara E,Marbury T

更新日期：2010-06-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Milrinone is the drug of choice for the treatment and prevention of low cardiac output syndrome (LCOS) in paediatric patients after open heart surgery across Europe. Discrepancies, however, among prescribing guidance, clinical studies and practice pattern require clarification to ensure safe an...

journal_title：Clinical pharmacokinetics

authors： Vogt W

更新日期：2014-01-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to assess the pharmacokinetic and pharmacodynamic behavior of ticagrelor administered either as crushed (in the semi-upright sitting position) or as integral (in the supine position) tablets in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percu...

journal_title：Clinical pharmacokinetics

authors： Alexopoulos D,Barampoutis N,Gkizas V,Vogiatzi C,Tsigkas G,Koutsogiannis N,Davlouros P,Hahalis G,Nylander S,Parodi G,Xanthopoulou I

更新日期：2016-03-01 00:00:00

abstract：:Aminoglycosides are important antibacterial agents for the treatment of serious infection. Evidence suggests that high peak plasma concentrations must be achieved early in the course of treatment if these agents are to be effective, but prolonged high concentrations may cause ototoxicity and nephrotoxicity. Peak plasm...

journal_title：Clinical pharmacokinetics

authors： Barclay ML,Begg EJ,Hickling KG

更新日期：1994-07-01 00:00:00

abstract：:Haloperidol has been used extensively for the treatment of psychotic disorders, and it has been suggested that the monitoring of plasma haloperidol concentration is clinically useful. Different assay methodologies have been used in research and clinical practice to examine the relationship between response and plasma ...

journal_title：Clinical pharmacokinetics

authors： Froemming JS,Lam YW,Jann MW,Davis CM

更新日期：1989-12-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Clearance is an important pharmacokinetic concept for scaling dosage, understanding the risks of drug-drug interactions and environmental risk assessment in children. Accurate clearance scaling to children requires prior knowledge of adult clearance mechanisms and the age-dependence of physiolo...

journal_title：Clinical pharmacokinetics

authors： Edginton AN,Schmitt W,Voith B,Willmann S

更新日期：2006-01-01 00:00:00

abstract：:The pharmacokinetics of CRP was tested in small short-term studies in both healthy volunteers and in subjects with schizophrenia, with similar results [242]. ...

journal_title：Clinical pharmacokinetics

authors： Mauri MC,Paletta S,Di Pace C,Reggiori A,Cirnigliaro G,Valli I,Altamura AC

更新日期：2019-09-01 00:00:00

abstract：:Analogues of human insulin have been developed to more closely replicate the physiology of meal-related and basal insulin secretion. Three rapid-acting analogues and two basal analogues are available for clinical use. Insulin aspart and insulin lispro have nearly identical pharmacokinetic and pharmacodynamic profiles ...

journal_title：Clinical pharmacokinetics

authors： Roach P

更新日期：2008-01-01 00:00:00

abstract：:Clarithromycin is a semisynthetic macrolide antibiotic, structurally related to erythromycin. It has a more favourable pharmacokinetic profile than erythromycin, thus allowing twice-daily administration and possibly increasing compliance among outpatients. Clarithromycin is well absorbed from the gastrointestinal trac...

journal_title：Clinical pharmacokinetics

authors： Fraschini F,Scaglione F,Demartini G

更新日期：1993-09-01 00:00:00

abstract：:Data on the pharmacokinetics of ofloxacin in chronic renal failure, in patients who were not dialysed or were receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), are reviewed. In addition, a large pool of data obtained in patients with a wide range of renal dysfunction is provided. The good ab...

journal_title：Clinical pharmacokinetics

authors： Lameire N,Rosenkranz B,Malerczyk V,Lehr KH,Veys N,Ringoir S

更新日期：1991-11-01 00:00:00

abstract：:Histamine H2-receptor antagonists are a unique class of compounds. Pharmacologically they are characterised as a family by their ability to inhibit the secretion of gastric acid, and kinetically they are classified as a family by their similarity in absorption, distribution and elimination. All the H2-receptor antagon...

journal_title：Clinical pharmacokinetics

authors： Lin JH

更新日期：1991-03-01 00:00:00

abstract：INTRODUCTION:Neglected tropical diseases (NTDs) affect more than one billion people, mainly living in developing countries. For most of these NTDs, treatment is suboptimal. To optimize treatment regimens, clinical pharmacokinetic studies are required where they have not been previously conducted to enable the use of ph...

journal_title：Clinical pharmacokinetics

authors： Verrest L,Dorlo TPC

更新日期：2017-06-01 00:00:00

abstract：:There are many pathological changes in patients with cystic fibrosis (CF) which can lead to alterations in drug disposition. Although, in patients with CF, the extent of drug absorption varies widely and the rate of absorption is slower, bioavailability is not altered. Plasma protein binding for the majority of drugs ...

journal_title：Clinical pharmacokinetics

authors： Rey E,Tréluyer JM,Pons G

更新日期：1998-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Taurolidine is known to have antimicrobial activity. Furthermore, at lower concentrations, it has been found to exert a selective antineoplastic effect in vitro and in vivo. The aim of this study was to investigate the pharmacokinetics of taurolidine in vivo following repeated intravenous infus...

journal_title：Clinical pharmacokinetics

authors： Stendel R,Scheurer L,Schlatterer K,Stalder U,Pfirrmann RW,Fiss I,Möhler H,Bigler L

更新日期：2007-01-01 00:00:00

abstract：OBJECTIVE:The aim of these studies was to determine the absolute bioavailability in healthy volunteers of inhaled fluticasone propionate (FP) administered as a single dose via the Diskhaler and Diskus powder devices, and the pharmacokinetics of inhaled FP after repeated administration via the Diskhaler device. METHODS...

journal_title：Clinical pharmacokinetics

authors： Mackie AE,McDowall JE,Falcoz C,Ventresca P,Bye A,Daley-Yates PT

更新日期：2000-01-01 00:00:00

abstract：:Following administration of equivalent oral doses (30mg) of either prednisone or prednisolone to 5 patients with chronic active liver disease who had failed to respond to therapy, 5 patients with chronic active liver disease in remission induced by prednisone, and 7 healthy volunteers, corticosteroid concentrations we...

journal_title：Clinical pharmacokinetics

authors： Uribe M,Summerskill WH,Go VL

更新日期：1982-09-01 00:00:00

abstract：:Hepatic and renal insufficiency due to co-infection, alcoholism, diabetes mellitus, family history, adverse effects of antiretrovirals and other factors are commonly seen in HIV-infected patients. Therefore, the use of antiretrovirals in this patient setting requires attention to the pharmacokinetic issues that clinic...

journal_title：Clinical pharmacokinetics

authors： McCabe SM,Ma Q,Slish JC,Catanzaro LM,Sheth N,DiCenzo R,Morse GD

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Dalcetrapib, a cholesteryl ester transfer protein (CETP) modulator, is a thioester pro-drug that is rapidly hydrolysed to generate a pharmacologically active thiol. The thiol covalently binds to plasma proteins as mixed disulfides, extensively distributes into plasma lipoprotein fractions, and ...

journal_title：Clinical pharmacokinetics

authors： Phelan M,Anzures-Cabrera J,Carlile DJ,Rowell L,Kuhlmann O,Arold G,Robson R,Bentley D

更新日期：2013-04-01 00:00:00

abstract：:Thienopyridines are inactive prodrugs that are converted in vivo to active metabolites, which irreversibly bind to and inactivate platelet P2Y(12) receptors, and inhibit platelet activation and aggregation. Prasugrel is a third-generation thienopyridine, recently approved for prevention of thrombotic cardiovascular co...

journal_title：Clinical pharmacokinetics

authors： Small DS,Farid NA,Payne CD,Konkoy CS,Jakubowski JA,Winters KJ,Salazar DE

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:Bitopertin (RG1678) is a glycine reuptake inhibitor currently in phase 3 trials for treatment of schizophrenia. This paper describes the use of physiologically based pharmacokinetic (PBPK) modelling and preclinical data to gain insights into and predict bitopertin clinical pharmacokinetics. METHODS:Simulati...

journal_title：Clinical pharmacokinetics

authors： Parrott N,Hainzl D,Alberati D,Hofmann C,Robson R,Boutouyrie B,Martin-Facklam M

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Recent analysis revealed strong associations between prostate-specific antigen (PSA) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) and supported PSA dynamics as bridging surrogacy endpoints for clinical benefit from treatment with abiraterone ace...

journal_title：Clinical pharmacokinetics

authors： Xu XS,Ryan CJ,Stuyckens K,Smith MR,Saad F,Griffin TW,Park YC,Yu MK,De Porre P,Vermeulen A,Poggesi I,Nandy P

更新日期：2017-01-01 00:00:00

abstract：:Since up to 90% of a theophylline dose is biotransformed, drugs influencing microsomal enzyme systems in the liver may affect the elimination of theophylline. Other integrated mechanisms (e.g. hepatic uptake) may also be altered by concurrent administration of other drugs. Whatever the mechanism, the interaction may b...

journal_title：Clinical pharmacokinetics

authors： Jonkman JH,Upton RA

更新日期：1984-07-01 00:00:00

abstract：:18 hypertensive patients with a glomerular filtration rate (GFR) between 3.8 and 113ml/min received guanfacine as single intravenous and multiple oral dose treatment. Mean plasma concentrations of guanfacine on the fifth day or oral treatment ranged from 6.5 to 8.6ng/ml in patients with normal renal function (GFR > 90...

journal_title：Clinical pharmacokinetics

authors： Kirch W,Köhler H,Braun W,von Gizycki C

更新日期：1980-09-01 00:00:00

abstract：OBJECTIVE:Although amikacin is primarily eliminated via glomerular filtration, drug concentrations are not consistently predicted in all patients. To better describe the relationship between amikacin clearance and both age and renal function, we used a new heuristic approach involving statistical analysis of dependence...

journal_title：Clinical pharmacokinetics

authors： Ducher M,Maire P,Cerutti C,Bourhis Y,Foltz F,Sorensen P,Jelliffe R,Fauvel JP

更新日期：2001-01-01 00:00:00

abstract：:Pharmacological treatment of patients with Alzheimer's disease is becoming more important, as evidenced by the number of drugs being developed in different countries. It has been shown in the majority of clinical trials that cholinesterase inhibitors, such as tacrine (tetrahydroaminoacridine), are able to induce benef...

journal_title：Clinical pharmacokinetics

authors： Parnetti L

更新日期：1995-08-01 00:00:00